Pfizer Inc.

-0.11 (-0.21%)
Products, Strategic Combinations, Regulatory

Pfizer, Morphosys And Incyte Enter Into Clinical Trial Collaboration For Monjuvi In Combination With TTI-622

Published: 06/13/2022 21:03 GMT
Pfizer Inc. (PFE) - Pfizer, Morphosys and Incyte Enter Into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination With Tti-622, a Fusion Protein Directed Against Cd47.
Incyte Corp - Collaboration is Effective Immediately Upon Execution of Agreement.
Incyte - Under Terms of Agreement, Pfizer Will Initiate a Multicenter, International Phase 1b/2 Study of Tti-622 With Monjuvi.
Incyte - Morphosys and Co Will Provide Monjuvi for Study, to Be Sponsored, Funded by Pfizer and Conducted in North America, Europe and Asia-pacific.